Boardman, OH, United States of America

JoLynn Barbara Giancola


Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
1 patent (USPTO):Explore Patents

Title: JoLynn Barbara Giancola: Innovator in Neuropharmacology

Introduction

JoLynn Barbara Giancola is a prominent inventor based in Boardman, Ohio. She has made remarkable contributions to the field of neuropharmacology, particularly through her innovative work on atypical inhibitors of monoamine transporters.

Latest Patents

Giancola holds a patent for her invention titled "Atypical inhibitors of monoamine transporters; method of making; and use thereof". This patent discloses a series of modafinil analogue compounds that exhibit moderate to high affinity for the dopamine transporter (DAT) and several analogues that also show affinity for the serotonin transporter (SERT) and/or sigma-1 receptor. The invention employs various functional groups such as aminopiperidine, piperidineamino, spirobicyclodiaza, or substituted piperazine, ensuring desired dopamine transporter affinity while enhancing metabolic stability. Importantly, these compounds possess no predicted addictive liability. Giancola's invention also outlines methods for treating substance use disorders and other neuropsychiatric conditions, including ADHD, depression, narcolepsy, and cognitive impairment.

Career Highlights

JoLynn Giancola works with the Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services. Her dedication to advancing medical research and therapeutic solutions has earned her recognition in the scientific community.

Collaborations

Throughout her career, Giancola has collaborated with notable colleagues, including Amy Hauck Newman and Rachel D Slack. These partnerships have enriched her research and have significantly contributed to the success of her innovative projects.

Conclusion

JoLynn Barbara Giancola’s work exemplifies the impactful intersection of science and innovation. Her patent for atypical inhibitors of monoamine transporters reflects a commitment to addressing critical neuropsychiatric disorders, underscoring the vital role of inventors in shaping the future of health and medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…